Larger-scale, well-designed randomized controlled trials with standardized protocols for intervention and assessment are crucial to providing more robust evidence on the impact of SGLT2 inhibitors on hypomagnesemia across various patient populations. This evidence concerns the gene SLC5A2 and familial primary hypomagnesemia.